OPPM
Opus Point Partners Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | $282K | Buy |
3,127
+115
| +4% | +$10.4K | 0.51% | 40 |
|
|
2019
Q2 | $254K | Buy |
3,012
+205
| +7% | +$17.3K | 0.38% | 57 |
|
|
2019
Q1 | $247K | Sell |
2,807
-179
| -6% | -$15.8K | 0.33% | 68 |
|
|
2018
Q4 | $213K | Sell |
2,986
-405
| -12% | -$28.9K | 0.47% | 35 |
|
|
2018
Q3 | $417K | Buy |
3,391
+326
| +11% | +$40.1K | 1% | 29 |
|
|
2018
Q2 | $301K | Sell |
3,065
-167
| -5% | -$16.4K | 0.65% | 36 |
|
|
2018
Q1 | $268K | Sell |
3,232
-972
| -23% | -$80.6K | 0.53% | 43 |
|
|
2017
Q4 | $326K | Sell |
4,204
-5,440
| -56% | -$422K | 0.28% | 40 |
|
|
2017
Q3 | $591K | Buy |
9,644
+4,469
| +86% | +$274K | 0.53% | 39 |
|
|
2017
Q2 | $238K | Sell |
5,175
-4,009
| -44% | -$184K | 0.22% | 51 |
|
|
2017
Q1 | $398K | Buy |
9,184
+3,047
| +50% | +$132K | 0.3% | 46 |
|
|
2016
Q4 | $238K | Buy |
6,137
+2,069
| +51% | +$80.2K | 0.19% | 50 |
|
|
2016
Q3 | $206K | Buy |
+4,068
| New | +$206K | 0.12% | 43 |
|